Using a CB1 blocker to treat kidney disease
A CB1 Antagonist for Treatment of Kidney Disease
['FUNDING_SBIR_2'] · MAKSCIENTIFIC, LLC · NIH-10922519
This study is looking at a new treatment using a medication called AM6588 to see if it can help improve kidney function and reduce symptoms in people with chronic kidney disease, especially those with diabetes.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MAKSCIENTIFIC, LLC (nih funded) |
| Locations | 1 site (BURLINGTON, UNITED STATES) |
| Trial ID | NIH-10922519 on ClinicalTrials.gov |
What this research studies
This research investigates the use of a CB1 receptor antagonist, AM6588, to treat chronic kidney disease (CKD), particularly diabetic kidney disease (DKD). The study aims to understand how blocking the CB1 receptor can improve kidney function and reduce symptoms like albuminuria and inflammation. By testing this treatment in rodent models of diabetes, researchers hope to demonstrate its effectiveness in slowing the progression of kidney damage. If successful, this approach could lead to new therapies for patients suffering from CKD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with diabetic kidney disease or chronic kidney disease.
Not a fit: Patients without diabetes or those with non-diabetic forms of kidney disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that slows the progression of kidney disease and improves overall kidney function.
How similar studies have performed: Previous studies have shown promising results with similar approaches using CB1 antagonists in animal models, indicating potential for success in human applications.
Where this research is happening
BURLINGTON, UNITED STATES
- MAKSCIENTIFIC, LLC — BURLINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ALAPAFUJA, SHAKIRU OLAJIRE — MAKSCIENTIFIC, LLC
- Study coordinator: ALAPAFUJA, SHAKIRU OLAJIRE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.